<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>The methotrexate drugs market is driven by rising autoimmune disease prevalence, technological advances in drug delivery, and increased availability of generics. Demand growth is fueled by the aging population and cost-effectiveness of methotrexate, while innovations like autoinjectors enhance long-term compliance.<div style="float:right;padding:0 0 15px 20px;margin:15px 0 20px 20px;width:300px">
 Methotrexate Drugs Market
 <figure>
 <img src="https://ml.globenewswire.com/Resource/Download/0ad97f26-baa3-4bbe-a859-4a194920ca60" title="Methotrexate Drugs Market" alt="Methotrexate Drugs Market" />
 <figcaption>Methotrexate Drugs Market</figcaption>
 </figure>
</div>Dublin, May 20, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6068246/methotrexate-drugs-global-strategic-business?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=nj8r83&amp;utm_campaign=2257847+-+Methotrexate+Drugs+Strategic+Business+Research+Report+2026%3a+Market+to+Surpass+%24600+Million+by+2032+-+Spotlight+as+a+Key+Chemotherapeutic+Agent%2c+Increasing+Prevalence+of+Autoimmune+Diseases&amp;utm_exec=chdomsai" rel="nofollow" target="_blank" title="Methotrexate Drugs - Global Strategic Business Report">"Methotrexate Drugs - Global Strategic Business Report"</a> has been added to ResearchAndMarkets.com's offering. The global market for Methotrexate Drugs was estimated at US$520.1 Million in 2025 and is projected to reach US$603.2 Million by 2032, growing at a CAGR of 2.1% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. <img alt="" height="400" src="//www.researchandmarkets.com/content-images/2506/2506866/1/methotrexate-drugs-market.png" width="600" /> Methotrexate is a potent antimetabolite and antifolate drug originally developed for cancer treatment but now widely used across multiple therapeutic areas. It functions by inhibiting the enzyme dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and cell replication. While it remains a cornerstone in chemotherapy regimens for certain cancers such as leukemia, lymphoma, and osteosarcoma, methotrexate has found extensive use in the management of autoimmune and inflammatory disorders due to its immunosuppressive properties. It is commonly prescribed in low doses for rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and systemic lupus erythematosus (SLE). Methotrexate is available in both oral and parenteral formulations (injectable and subcutaneous), offering dosing flexibility across clinical scenarios. In autoimmune diseases, it is often considered a first-line or anchor drug, particularly in the treatment of rheumatoid arthritis, where it is frequently combined with biologics or other disease-modifying antirheumatic drugs (DMARDs). In oncology, it is administered at high doses with leucovorin rescue to mitigate toxicity. The drug's ability to modulate immune responses and its cost-effectiveness have cemented its role in both developing and developed healthcare systems. Despite newer targeted therapies, methotrexate continues to be a preferred agent due to its long track record, established efficacy, and inclusion in numerous clinical guidelines. The Growth in the Methotrexate Drugs Market is Driven by Several Factors The growth in the methotrexate drugs market is driven by several factors, including the rising incidence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel diseases, which collectively contribute to increasing global demand for immunomodulatory treatments. The aging population, which is more susceptible to chronic inflammatory conditions, further supports market expansion. In oncology, methotrexate remains a vital part of multi-agent chemotherapy regimens, especially for pediatric leukemias and rare cancers, maintaining its relevance despite the rise of targeted therapies. The increased availability of low-cost generic formulations has significantly broadened access, particularly in low- and middle-income countries, enabling widespread adoption across therapeutic categories. Additionally, the emergence of patient-friendly delivery formats, such as subcutaneous autoinjectors and sustained-release injectables, is driving uptake among patients requiring long-term therapy. Favorable reimbursement policies, inclusion in national essential medicines lists, and support from global health organizations for chronic disease management also play a key role. Furthermore, rising awareness among healthcare providers and patients about early and aggressive management of autoimmune diseases is reinforcing methotrexate's position as a foundational treatment. These combined drivers are expected to sustain robust growth in the methotrexate drugs market over the foreseeable future. What Are the Market Dynamics and Evolving Trends Shaping Methotrexate Use? The methotrexate drugs market is evolving in response to changing therapeutic protocols, increasing prevalence of autoimmune diseases, and innovations in drug delivery. With autoimmune and chronic inflammatory disorders on the rise globally, the demand for reliable and affordable DMARDs like methotrexate is expanding steadily. Technological advances in parenteral delivery systems, such as autoinjectors and prefilled syringes, are enhancing patient compliance and expanding the use of injectable methotrexate in outpatient and home-care settings. These innovations are particularly significant for chronic therapy in conditions like rheumatoid arthritis, where long-term adherence is critical for disease management. Meanwhile, biosimilar and generic drug development is intensifying competition, especially in emerging markets where healthcare systems prioritize cost containment. The growing presence of methotrexate generics in Asia-Pacific, Latin America, and parts of Eastern Europe is making treatment more accessible while stimulating market penetration. Regulatory agencies such as the FDA and EMA have also streamlined approval pathways for generics and biosimilars, creating opportunities for local and international manufacturers. In addition, research is exploring the use of methotrexate in combination therapies, such as with TNF inhibitors or JAK inhibitors, to maximize clinical benefit and minimize disease progression. The drug is also being evaluated in novel indications and dose-optimization studies aimed at reducing toxicity while maintaining efficacy. Report Features: <ul><li>Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.</li><li>In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.</li><li>Company Profiles: Coverage of players such as Accord Healthcare Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Apotex Inc., Aurobindo Pharma Limited and more.</li><li>Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.</li></ul> Key Insights: <ul><li>Market Growth: Understand the significant growth trajectory of the Psoriasis Indication segment, which is expected to reach US$279.7 Million by 2032 with a CAGR of 2.8%. The Rheumatoid Arthritis Indication segment is also set to grow at 1.3% CAGR over the analysis period.</li><li>Regional Analysis: Gain insights into the U.S. market, valued at $160.9 Million in 2025, and China, forecasted to grow at an impressive 4.1% CAGR to reach $131.7 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.</li></ul> Report Scope <ul><li>Segments: Indication (Psoriasis, Rheumatoid arthritis, Cancer, Other indications); Drug Type (Branded, Generic); Drug Form (Tablet, Liquid, Injectable); Administration Route (Oral, Subcutaneous, Intramuscular, Intravenous); Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies).</li><li>Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.</li></ul> Key Attributes: <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Report Attribute</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">Details</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">No. of Pages</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">564</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecast Period</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2025 - 2032</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Estimated Market Value (USD) in 2025</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$520.1 Million</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecasted Market Value (USD) by 2032</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$603.2 Million</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Compound Annual Growth Rate</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2.1%</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regions Covered</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Global</td></tr></table> Key Topics Covered: MARKET OVERVIEW <ul><li>Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy</li><li>How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind</li><li>Methotrexate Drugs - Global Key Competitors Percentage Market Share in 2026 (E)</li><li>Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)</li></ul> MARKET TRENDS &amp; DRIVERS <ul><li>Increasing Prevalence of Autoimmune Diseases Spurs Demand for Methotrexate-Based Therapies</li><li>Growing Incidence of Cancer Worldwide Throws the Spotlight on Methotrexate as a Key Chemotherapeutic Agent</li><li>Rising Preference for Low-Cost Generic Oncology Drugs Expands Addressable Market Opportunity for Methotrexate</li><li>Strategic Collaborations Between Pharma Companies and CROs Drive Clinical Research and Methotrexate Drug Pipeline Expansion</li><li>Advancements in Drug Delivery Mechanisms Strengthen Business Case for Injectable Methotrexate Formulations</li><li>Surge in Pediatric Applications for Juvenile Arthritis Propels Growth in Specialized Methotrexate Dosage Forms</li><li>Inclusion of Methotrexate in WHO`s List of Essential Medicines Generates Demand Across Developing Markets</li><li>Growing Emphasis on Early RA Diagnosis and Intervention Drives Adoption of Methotrexate as First-Line Therapy</li><li>Health Insurance Coverage Expansion in Emerging Economies Sustains Growth in Methotrexate Treatment Uptake</li><li>Development of Biosimilar and Bioequivalent Methotrexate Formulations Accelerates Market Penetration</li><li>Rising Awareness Among Physicians and Patients Throws the Spotlight on Methotrexate Treatment Benefits</li></ul> COMPETITION: Some of the Companies Featured in This Methotrexate Drugs Market Report <ul><li>Accord Healthcare Inc.</li><li>Alembic Pharmaceuticals Limited</li><li>Amneal Pharmaceuticals LLC</li><li>Apotex Inc.</li><li>Aurobindo Pharma Limited</li><li>Bristol Myers Squibb</li><li>Cipla Limited</li><li>Dr. Reddy's Laboratories Ltd.</li><li>Eisai Co., Ltd.</li><li>Eli Lilly and Company</li><li>Hikma Pharmaceuticals PLC</li><li>LEO Pharma A/S</li><li>Merck &amp; Co., Inc.</li><li>Novartis AG (Sandoz)</li><li>Pfizer Inc.</li><li>Pharmascience Inc.</li><li>Sandoz Inc.</li><li>Sun Pharmaceutical Industries Ltd.</li><li>Teva Pharmaceutical Industries Ltd.</li><li>Zydus Lifesciences</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6068246/methotrexate-drugs-global-strategic-business?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=nj8r83&amp;utm_campaign=2257847+-+Methotrexate+Drugs+Strategic+Business+Research+Report+2026%3a+Market+to+Surpass+%24600+Million+by+2032+-+Spotlight+as+a+Key+Chemotherapeutic+Agent%2c+Increasing+Prevalence+of+Autoimmune+Diseases&amp;utm_exec=chdomsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/bbqt3p</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://ml.globenewswire.com/Resource/Download/0ad97f26-baa3-4bbe-a859-4a194920ca60" title="Methotrexate Drugs Market" rel="nofollow">Methotrexate Drugs Market</a>
 </li>
 </ul>
<pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NzA4ZmVhMzAtOWVkMS00NTNhLWJiZmEtMWIxYTdhYzkzZWI3LTEwMjY3MzctMjAyNi0wNS0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Methotrexate Drugs Strategic Business Research Report 2026: Market to Surpass $600 Million by 2032 - Spotlight as a Key Chemotherapeutic Agent, Increasing Prevalence of Autoimmune Diseases

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn